GUEST COLUMNISTS

• COGs And Biology, Two Endpoints Needlessly At Odds In Advanced Therapy

  Problems emerge when development, manufacturing, and clinical priorities fail to converge in cell and gene therapy development.

• All The Ways Global Biopharma Still Grapples With Annex 1

  Biopharma companies can't consistently meet Annex 1 expectations. At the heart of the problems, regulators have shifted the burden of proof to manufacturers.

• FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address

  For those involved in outsourcing, the new FDA draft guidance regarding FDA Form 483 observations reshapes the accountability framework. The public comment period ends May 8.

• Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables

  A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.

• Where Contamination Control Really Breaks Down In Practice

  Contamination control gaps arise when two dynamics merge — when processes become familiar and workloads increase. Here's how to spot them before they spin out of control.

• Trends In FDA FY 2025 Warning Letters

  The FDA issued a total of 303 warning letters to drug and biologics products in Fiscal Year 2025 (FY25), an increase from FY24. This article reveals key agency focal points and trends.

• SUS Interchangeability Assessment And Qualification Best Practices

  Establishing a robust single-use systems (SUS) interchangeability program can be a pivotal feature of a supply chain resiliency initiative.

• Delivery Strategy For Next-Gen Cardiac Gene Therapies

  As the field matures, the most transformative gene therapies in heart health are treating delivery not as an afterthought but as a fundamental principle.